Effectiveness of GLP ‐ 1RA according to different type 2 diabetes phenotypes: A retrospective study
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.70005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Irene Caruso und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, Uni…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Type 2 diabetes (T2D) is a heterogeneous disease, with varying pathogenetic mechanisms influencing treatment response. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) offer clear metabolic benefits in T2D, but interindividual variability in response is observed. This retrospective study investigated whether GLP‐1RA effectiveness varies by T2D phenotypes (severe insulin‐deficient diabetes [SIDD], severe insulin‐resistant diabetes [SIRD], mild obesity‐related diabetes [MOD], mild age‐related diabetes [MARD]) and assessed predictors of HbA1c reduction. Materials and Methods Individuals attending the Endocrinology Unit at the University Hospital Policlinico Consorziale in Bari, Italy, between 01 January 2014, and 31 August 2024, were evaluated for participation. T2D phenotypes were assigned using the algorithm by Bello‐Chavolla. The primary outcome was the difference in HbA1c change from baseline among phenotypes, and predictors were identified using SHAP and multivariable regression. Time to treatment failure (HbA1c >7.0%) was estimated with Kaplan–Meier analysis.
Results
Among 181 patients, SIDD individuals yielded a significantly greater HbA1c reduction (−2.6%[1.9]) versus other phenotypes ( p < 0.0001). Baseline HbA1c was the strongest predictor of HbA1c reduction. SIDD was linked to faster treatment failure (HR 3.69, 95% CI 1.37–9.94; p < 0.01), but this effect disappeared after adjustment for baseline HbA1c.
Conclusion
This study adds to the emerging evidence against the hard clustering approach to T2D phenotyping in terms of response to treatment and time to treatment failure, particularly with GLP‐1RA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
ORCID-Profile: Sergio Di Molfetta, Gian Pio Sorice, Francesco Giorgino
Förderung
- NextGenerationEU
Zitieren
APA
Caruso, I., Giordano, F., Matichecchia, I. I., Di Gioia, L., Di Molfetta, S., Cignarelli, A., Sorice, G. P., Natalicchio, A., Laviola, L., & Giorgino, F. (2025). Effectiveness of GLP ‐ 1RA according to different type 2 diabetes phenotypes: A retrospective study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70005
Vancouver
Caruso I, Giordano F, Matichecchia II, Di Gioia L, Di Molfetta S, Cignarelli A, et al. Effectiveness of GLP ‐ 1RA according to different type 2 diabetes phenotypes: A retrospective study. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70005
BibTeX
@article{Caruso2025,
author = {Caruso, Irene and Giordano, Fiorella and Matichecchia, Immacolata Ilaria and Di Gioia, Ludovico and Di Molfetta, Sergio and Cignarelli, Angelo and Sorice, Gian Pio and Natalicchio, Annalisa and Laviola, Luigi and Giorgino, Francesco},
title = {Effectiveness of GLP ‐ 1RA according to different type 2 diabetes phenotypes: A retrospective study},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.70005}
}
EUVIMED